References
- Sesler JM. Stress-related mucosal disease in the intensive care unit. An update on prophylaxis. AACN Adv Crit Care 2007;18:119-28
- Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care 2005;20:35-45
- Daley RJ, Rebuck JA, Welage LS, et al. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004;32:2008-13
- Cook DJ, Huller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994;330:377-81
- Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327
- Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse 2006;26:18-29
- Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005;33:760-5
- Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005;39:1667-77
- Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999;94:351-7
- Pisegna JR, Sostek MB, Monyak JT, et al. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg in controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther 2008;27:483-90
- Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-72
- Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20
- Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three way crossover study. Aliment Pharmacol Ther 2004;20:399-406
- Martin LF, Booth FV, Karlstadt BG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993;21:19-30
- Wilder-Smith C, Röhss K, Bondarov P, et al. Intravenous esomeprazole 40 mg is effective for the control of intragastric acid levels whether given as a 3-minute injection or a 30-minute infusion. Clin Drug Invest 2005;25:517-25
- Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically ill patients. Am J Gastroenterol 1997;92:79-83
- Cloud ML, Offen W. Continuous infusions of nizatidine are safe and effective in the treatment of intensive care unit patients at risk for stress gastritis. Scand J Gastroenterol Suppl 1994;206:29-34
- Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102:2648-54
- Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006;101:1964-71
- Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-60
- Smith CL, Bardgett DM, Hunter JM. Haemodynamic effects of the i.v. administration of cimetidine or ranitidine in the critically ill patients. A double-blind prospective study. Br J Anaesth 1987;59:1397-1402
- Somberg L, Morris J Jr, Fantus R, et al. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma 2008;64:1202-10
- Tagamet [package insert]. Boronia, Australia: GlaxoSmithKline, 2007
- Zegerid [package insert]. Whitby, Canada: Santarus, Inc.,2008